Time filter

Source Type

Singh M.,National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR | Jadaun G.P.S.,National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR | Ramdas,National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR | Srivastava K.,National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR | And 10 more authors.
Indian Journal of Medical Research | Year: 2011

In drug resistant, especially multi-drug resistant (MDR) tuberculosis, fluoroquinolones (FQs) are used as second line drugs. However, the incidence of FQ-resistant Mycobacterium tuberculosis is rapidly increasing which may be due to extensive use of FQs in the treatment of various other diseases. The most important known mechanism i.e., gyrA mutation in FQ resistance is not observed in a significant proportion of FQ resistant M. tuberculosis isolates suggesting that the resistance may be because of other mechanisms such as an active drug efflux pump. In this study we evaluated the role of the efflux pumps in quinolone resistance by using various inhibitors such as carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP) and verapamil, in clinical isolates of M. tuberculosis.

Loading National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR collaborators
Loading National JALM Institute for Leprosy and Other Mycobacterial Diseases ICMR collaborators